Study of FTY720 in Patients With Uveitis

• Status: Withdrawn
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• Acute noninfectious posterior, intermediate, or pan uveitis

• Vitreous haze score of 1+ or more in the study eye at screening and baseline visits

Exclusion Criteria:

• Vaso-occlusive vasculitis involving the retinal macula

• Behçet's uveitis

• Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)

• Other protocol defined inclusions and/or exclusions may apply.